How is bladder urothelial carcinoma staged?

Staging of Bladder Urothelial Carcinoma

For muscle-invasive bladder cancer, perform CT of the chest, abdomen, and pelvis (including CT urography with designated phases) for comprehensive staging. 1

Pathologic Staging Framework

Bladder urothelial carcinoma staging follows the AJCC 8th edition TNM system 2, which provides critical treatment guidance:

T Category (Local Tumor Extent)

• Ta: Non-invasive papillary carcinoma
• Tis: Carcinoma in situ (flat tumor)
• T1: Invasion into lamina propria (substaging of pT1 should be attempted, though no single method is formally recommended) 2
• T2: Muscle invasion
  • T2a: Superficial muscle (inner half)
  • T2b: Deep muscle (outer half)
• T3: Invasion into perivesical tissue
• T4: Invasion into adjacent organs (prostate, uterus, vagina, pelvic/abdominal wall)

N Category (Lymph Node Involvement)

The AJCC 8th edition made a critical change: perivesical lymph node involvement is now classified as N1 (previously considered more advanced disease) 2

M Category (Distant Metastases)

• M1a: Non-regional lymph nodes only
• M1b: Other distant metastases 2

Imaging Algorithm for Staging

For Muscle-Invasive Disease (T2 or Higher)

Primary staging modality: CT chest, abdomen, and pelvis with CT urography protocol 1

• This single study evaluates:
  • Local tumor extent
  • Lymph node involvement (abdominal and pelvic)
  • Distant metastases
  • Synchronous upper tract disease

Alternative if CT contraindicated: MRI (contrast allergy or radiation concerns) 1, 3

For Differentiating T1 from T2 Disease

MRI using the VI-RADS scoring system is the preferred modality 1

• This distinction is clinically critical as it determines whether bladder-sparing approaches (TURBT + intravesical therapy) versus radical cystectomy is appropriate
• CT has limited accuracy for this specific differentiation 4

Role of PET/CT

Not routinely recommended for initial staging in cN0 disease 1

However, PET/CT may provide value in:

• Patients with suspected pelvic lymph node metastases (guides local treatment decisions) 1
• Evaluating distant metastases when conventional imaging is equivocal
• Clinical trial settings for neoadjuvant immunotherapy selection 1

Essential Pathologic Requirements

The pathology report must specify 1:

• Tumor grade (high vs. low grade per WHO 2016/2022 classification)
• Depth of invasion (precise T stage)
• Presence of lamina propria in specimen (critical for confirming T1 vs. Ta)
• Presence of muscle tissue (confirms adequacy for T2 assessment)

Common Pitfall

Incomplete initial TURBT: If no muscle is present in the specimen or T1 disease is identified, a repeat TURBT within 2-6 weeks is mandatory 5. This restaging procedure is essential because:

• Initial resection may be incomplete
• Upstaging occurs in 20-30% of cases
• Accurate staging fundamentally changes treatment (intravesical therapy vs. cystectomy)

Prostatic Urethral Evaluation

Biopsy the prostatic urethra when 1:

• Bladder neck tumor is present
• Carcinoma in situ is present or suspected
• Positive cytology without visible bladder tumor
• Visible prostatic urethral abnormalities

This assessment is critical for determining eligibility for orthotopic neobladder reconstruction.

Upper Tract Surveillance

CT urography is essential to evaluate for synchronous upper tract urothelial carcinoma 3, which occurs in 25-30% of cases and is often high-grade invasive disease at presentation 3.

Risk Stratification Impact

Once staged, patients are stratified into risk categories (low, intermediate, high, very high) using validated scoring systems 5. This stratification directly determines:

• Frequency and type of intravesical therapy
• Duration of BCG treatment (1 vs. 3 years)
• Timing of radical cystectomy consideration

Very high-risk features warranting immediate cystectomy consideration include: T1 with concurrent CIS, lymphovascular invasion, variant histology, or BCG-unresponsive disease 5.